InNexus Biotechnology Inc. Announces Business Development Initiative for DXL625

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX Venture:IXS) (www.ixsbio.com), a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, announced today that the Company will embark on a business development initiative for DXL625™ (CD20), the Company’s lead preclinical candidate for the prospective treatment of Non-Hodgkin’s Lymphoma and/or Chronic Lymphocytic Leukemia.

MORE ON THIS TOPIC